"instanceType","uuid:ID","description","id","label","name","rationale"
"StudyDesign","06be4bf9-b346-4b12-a9f2-cb53187d718a","The main design for the study","StudyDesign_1","","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
